课题基金 / 基金详情

P-2: Inhibitors of N-cahedrin in the treatment of pancreatic cancer

P-2: Inhibitors of N-cahedrin in the treatment of pancreatic cancer
P-2:N-caedrin 抑制剂治疗胰腺癌
批准号:
8328170
负责人:
KEITH R JOHNSON
金额:
$15.76万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-09-01 至 2013-08-31

项目摘要

项目成果

KEITH R JOHNSON的其他基金

相似基金

相关文献

中文摘要
翻译
胰腺癌是最致命的癌症之一,因为它广泛侵袭到 周围组织和远处器官的转移,甚至在肿瘤进展的早期阶段也是如此。穷人 这种恶性肿瘤的预后也反映出对目前治疗的反应普遍较差。因此,一个基本的 了解这些肿瘤的生物学和促进其侵袭和转移的机制 肿瘤转移将为发展新的诊断和治疗方法提供基础。 胰腺癌的特点是细胞外基质广泛沉积,它可以 对细胞行为有深远的影响。我们有初步研究表明,细胞来源于 胰腺癌在体外对外源性I型胶原的转化反应 从不活动的上皮细胞到高度运动和侵袭性的间充质细胞。上皮性癌的一个标志 间充质转化是N-钙粘蛋白的表达增加,这是我们和其他人展示的一种蛋白质 促进肿瘤细胞的侵袭。对目前的提议具有特别重要意义的是,N-钙粘附素由下式表达 超过50%的侵袭性胰腺肿瘤。 最近的研究表明,由Adherex Technologies开发的N-钙粘素拮抗剂Exherin? 北卡罗来纳州达勒姆公司在体外和体内抑制N-钙粘附素的活性。我们假设艾希林?是 能够抑制N-钙粘附素诱导的肿瘤细胞的运动,并建议在Ncadherin- 胰腺癌细胞在细胞运动的组织培养模型和小鼠模型中的表达 侵袭性胰腺癌。此外,我们建议表征下游的信号通路。 促进N-钙粘蛋白上调和侵袭的I型胶原,目的是识别潜在的 可与Exherin联合治疗的抑制剂。最后,我们将测试一下 Exherin?作为治疗人胰腺癌的临床试验。
英文摘要
Pancreatic adenocarcinomas are among the most fatal cancers because of their extensive invasion into surrounding tissues and metastasis to distant organs, even at an early stage of tumor progression. The poor prognosis of this malignancy also reflects a generally poor response to current therapies. Thus, a basic understanding of the biology of these tumors and the mechanisms that promote their invasion and metastasis will provide a basis for developing new methods for diagnosis and treatment. Pancreatic adenocarcinomas are characterized by extensive deposition of extracellular matrix, which can have profound effects on cell behavior. We have preliminary studies showing that cells derived from pancreatic adenocarcinomas respond in vitro to exogenous collagen type I by undergoing a transformation From a non-motile epithelial cell to a highly motile and invasive mesenchymal cell. A hallmark of epithelial to mesenchymal transitions is increased expression of N-cadherin, a protein we and others have shown promotes tumor cell invasion. Of particular significance to the current proposal, N-cadherin is expressed by more than 50% of invasive pancreatic tumors. Recent studies have shown that the N-cadherin antagonist, Exherin¿, developed by Adherex Technologies, Inc. Durham, NC, inhibits the activity of N-cadherin in vitro and in vivo. We hypothesize that Exherin¿ is capable of inhibiting N-cadherin-induced motility in tumor cells, and propose to test this hypothesis in Ncadherin- expressing pancreatic cancer cells in a tissue culture model of cell motility, and in a mouse model of invasive pancreatic cancer. In addition, we propose to characterize the signaling pathways downstream of collagen I that promote up-regulation of N-cadherin and invasion, for the purpose of identifying potential inhibitors that could be used in combination therapy with Exherin¿. Finally, we will test the efficacy of Exherin¿ as a treatment for human pancreatic cancer in clinical trials.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Studies on Cadherin/Catenin Complexes
Nebraska Center for Cellular Signaling
Nebraska Center for Cellular Signaling
Nebraska Center for Cellular Signaling
国内基金
海外基金
多模态超声VisTran-Attention网络评估早期子宫颈癌保留生育功能手术可行性
  • 批准号:
    --
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30万元
  • 批准年份:
    2022
  • 负责人:
    郑巧
  • 依托单位:
Ultrasomics-Attention孪生网络早期精准评估肝内胆管癌免疫治疗的研究
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    52万元
  • 批准年份:
    2022
  • 负责人:
    陈立达
  • 依托单位:
多模态超声VisTran-Attention网络评估早期子宫颈癌保留生育功能手术可行性
  • 批准号:
    82202156
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.0万元
  • 批准年份:
    2022
  • 负责人:
    郑巧
  • 依托单位: